All AbMole products are for research use only, cannot be used for human consumption.
GSK1292263 is a novel GPR119 receptor agonist used for the treatment of type 2 diabetes. In the intravenous glucose tolerance test, significant increases in the peak insulin response and insulin AUC (0-15 min) of 30-60% were reported in the GSK1292263 treatment group, compared with values in the vehicle control cohort. This insulin upregulation correlated with a significant increase in the glucose disposal rate.
 |
Source | Eur J Pharmacol (2017). Figure 2. GSK1292263 |
| Method | i.v. | |
| Cell Lines | mice | |
| Concentrations | 30 mg/kg | |
| Incubation Time | 0 to 4 h | |
| Results | Our findings also demonstrated that all three GPR119 agonists (APD668, GSK1292263 and MBX2982) tested improved fat tolerance suggesting a GPR119 receptor mediated effect |
| Cell Experiment | |
|---|---|
| Cell lines | |
| Preparation method | |
| Concentrations | |
| Incubation time | |
| Animal Experiment | |
|---|---|
| Animal models | male Sprague-Dawley rats |
| Formulation | 0.9% sodium chloride solution |
| Dosages | 3-30 mg/kg |
| Administration | |
| Molecular Weight | 456.56 |
| Formula | C23H28N4O4S |
| CAS Number | 1032823-75-8 |
| Solubility (25°C) | DMSO 22 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
[2] Jin Won Yang, et al. GPR119: a promising target for nonalcoholic fatty liver disease
| Related GPR/FFAR Products |
|---|
| GW9508
GW9508 is a potent and selective G protein-coupled receptors FFA1 (GPR40) and GPR120 agonist with pEC50s of 7.32 and 5.46, respectively. GW9508 has anti-inflammatory and anti-atherosclerotic activities. GW9508 is a glucose-sensitive insulin secretagogue and an ATP-sensitive potassium (KATP) channels opener. |
| Fasiglifam (TAK-875) Hemihydrate
Fasiglifam (TAK-875) Hemihydrate is a novel, orally available, selective GPR40 agonist. |
| OC000459
OC000459 is a potent, selective, and orally active D prostanoid receptor 2 antagonist. |
| AMG-837
AMG 837 is a potent, orally bioavailable GPR40 agonist with EC50 of 14 nM. |
| AZD1981
AZD1981 is a potent, selective CRTh2 (DP2) receptor antagonist with IC50 of 4 nM, showing >1000-fold selectivity over more than 340 other enzymes and receptors, including DP1. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
